SCHEMBL4050049

SCHEMBL4050049

CCOC(=O)C(O)CNC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
SYK P43405 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
SERPINE1 P05121 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA12 O43570 2/20 0.38
CA9 Q16790 2/20 0.38
CTSK P43235 2/20 0.38
CTSS P25774 1/20 0.38
CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7403514 0.86 MEN1 (0.45) SYKMEN1KMT2AGAATDP1
SCHEMBL14155384 0.86 MEN1 (0.45) SYKMEN1KMT2AGAATDP1
SCHEMBL14015716 0.86 MEN1 (0.45) SYKMEN1KMT2AGAATDP1
SCHEMBL27800430 0.83 CTSK (0.43) CYP1A2CYP2C9CYP2C19HTTSYK
SCHEMBL30356846 0.83 SYK (0.39) CYP1A2CYP2C9CYP2C19HTTSYK
SCHEMBL8465153 0.83 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19HTTSYK
SCHEMBL28220300 0.83 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19HTTSYK
SCHEMBL6224692 0.83 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19HTTSYK
SCHEMBL12610620 0.82 SYK (0.40) CYP1A2CYP2C9CYP2C19HTTSYK
SCHEMBL26644676 0.82 CYP1A2 (0.42) CYP1A2CYP2C9CYP2C19HTTSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758585-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-07-22 EP disclosed
US-7476666-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-01-13 US disclosed
US-20080015187-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-17 US disclosed
EP-1758585-A2 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2007-03-07 EP disclosed
WO-2005120516-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015187-A1 Hiv Integrase Inhibitors REV1, ZC3HAV1, PNP CYP1A2 1172/4885CYP2C9 886/4885CYP2C19 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.